

Generic drugs - safe, effective, and affordable

Dermatologic Therapy

22, 229-240

DOI: [10.1111/j.1529-8019.2009.01236.x](https://doi.org/10.1111/j.1529-8019.2009.01236.x)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Consequences of Switching 5 α -Reductase Inhibitors on Prostate Specific Antigen Velocity. Journal of Urology, 2010, 184, 218-223.	0.2	5
3	Should we have concerns with generic versus brand antimicrobial drugs? A review of issues. Journal of Pharmaceutical Health Services Research, 2011, 2, 135-150.	0.3	8
4	Exploring community pharmacists's views on generic medicines: a nationwide study from Malaysia. International Journal of Clinical Pharmacy, 2011, 33, 124-131.	1.0	31
5	Biopharmaceuticals and biosimilars in psoriasis: What the dermatologist needs to know. Journal of the American Academy of Dermatology, 2012, 66, 317-322.	0.6	55
6	Generic drugs in dermatology. Journal of the American Academy of Dermatology, 2012, 66, 343.e1-343.e8.	0.6	5
7	Generic drugs in dermatology. Journal of the American Academy of Dermatology, 2012, 66, 353.e1-353.e15.	0.6	6
8	Off-Patent Generic Medicines vs. Off-Patent Brand Medicines for Six Reference Drugs: A Retrospective Claims Data Study from Five Local Healthcare Units in the Lombardy Region of Italy. PLoS ONE, 2013, 8, e82990.	1.1	21
9	Generic - equivalent drugs use in internal and general medicine patients: distrust, confusion, lack of certainties or knowledge? Part 1. Pharmacological issues. Italian Journal of Medicine, 2014, 8, 80.	0.2	3
10	Generic - equivalent drugs use in internal and general medicine patients: distrust, confusion, lack of certainties or of knowledge? Part 3. Clinical issues. Italian Journal of Medicine, 2014, 8, 99.	0.2	2
11	Generic - equivalent drugs use in internal and general medicine patients: distrust, confusion, lack of certainties or of knowledge? Part 2. Misconceptions, doubts and critical aspects when using generic drugs in the real world. Italian Journal of Medicine, 2014, 8, 88.	0.2	7
12	Contemporary generic market in Japan " key conditions to successful evolution. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 181-194.	0.7	41
13	FDA Bioequivalence Standards. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , .	0.2	14
14	Good Clinical Practice. , 2014, , 756-787.		0
15	Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. European Journal of Clinical Pharmacology, 2015, 71, 549-567.	0.8	166
16	Comparative Risk Assessment of Formulation Changes in Generic Drug Products: A Pharmacology/Toxicology Perspective. Toxicological Sciences, 2015, 146, 2-10.	1.4	10
17	Navigating the Dermatological Drug Cost Curve. JAMA - Journal of the American Medical Association, 2016, 315, 2724.	3.8	1
18	Clinical, Pharmacokinetic, and In Vitro Studies to Support Bioequivalence of Ophthalmic Drug Products. AAPS Journal, 2016, 18, 1032-1038.	2.2	30
19	Students and Doctors are Unaware of the Cost of Drugs they Frequently Prescribe. Basic and Clinical Pharmacology and Toxicology, 2017, 120, 278-283.	1.2	20

#	ARTICLE	IF	CITATIONS
20	Dissecting drug pricing: Supply chain, market, and nonmarket trends impacting clinical dermatology. Journal of the American Academy of Dermatology, 2020, 83, 691-699.	0.6	2
21	Current regulatory scenario and alternative surrogate methods to establish bioequivalence of topical generic products. Journal of Drug Delivery Science and Technology, 2021, 61, 102090.	1.4	5
22	Medicaid and Medicare Part B spending on immunomodulators and biosimilars. Journal of Dermatological Treatment, 2021, , 1-3.	1.1	0
23	Clinical Endpoint Bioequivalence Study. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 243-274.	0.2	3
24	SELECT: Evaluation and Implementation of Clinical Practice Guidelines. Advances in Skin and Wound Care, 2010, 23, 161-168.	0.5	4
25	10.5937/mckg48-5071 = Recent developments in the world's leading generic markets. Medicinski Casopis, 2014, 48, 140-142.	0.1	3
26	Generic Substitution Issues: Brand-generic Substitution, Generic-generic Substitution, and Generic Substitution of Narrow Therapeutic Index (NTI)/Critical Dose Drugs. MÃ¡dica, 2011, 6, 52-8.	0.4	9
27	Generic vs brand originator alendronate: analysis of persistence and compliance in five Local Healthcare Units in the Lombardy Region of Italy. Clinical Cases in Mineral and Bone Metabolism, 2013, 10, 195-8.	1.0	5
28	[Not Available]. Journal of Clinical and Aesthetic Dermatology, 2015, 8, S2-S14.	0.1	0
30	Predictors of substitution to generic drugs and physiciansâ€™ perceived exclusivity of substitution: A cross sectional survey among physicians. Journal of Generic Medicines, 0, , 174113432211075.	0.0	2